Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag085 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, 2026. Verfasst von Letizia Procaccio und 31 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, 35128, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel, Albumins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ricerca Corrente funding from the Italian Ministry of Health, Associazione Italiana per la Ricerca sul Cancro (AIRC), Italian Ministry of University and Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
International guidelines recommend 5FU/LV, Nal-IRI + 5FU/LV, FOLFIRI, FOLFOX, or (m)FOLFIRINOX as second-line (2L) chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after failure of gemcitabine+Nab-paclitaxel (GnP). However, a head-to-head comparison has not been performed. Patients and methods We conducted an observational cohort study of consecutive mPDAC patients treated with 2L chemotherapy after GnP failure at 41 Italian centers. Progression-free survival (PFS) and overall survival (OS) were compared using inverse probability of treatment weighting. Interpretable artificial intelligence methods were applied to optimize treatment allocation. A counterfactual Cox model was trained on baseline characteristics to estimate 12-month PFS under each regimen, and an Optimal Policy Tree (OPT) was derived to generate treatment recommendations, validated in a test set. Net-benefit curves evaluated clinical utility.
Results
Among 704 eligible patients, 56 (8.0%) received 5FU/LV, 153 (21.7%) FOLFIRI, 209 (29.7%) FOLFOX, 209 (29.7%) Nal-IRI + 5FU/LV, and 77 (10.9%) FOLFIRINOX. FOLFIRINOX was associated with the longest PFS and OS. Median PFS was comparable among doublets (3.5 months FOLFOX, 3.6 FOLFIRI, 3.3 Nal-IRI + 5FU/LV), though Nal-IRI + 5FU/LV showed a long-term benefit. The OPT recommended Nal-IRI + 5FU/LV for patients with head/body tumors, Eastern Cooperative Oncology Group performance status (PS) 0, or CA19.9 < 109 U/mL in those with PS > 0. Net-benefit analysis showed that the OPT consistently outperformed uniform treatment strategies, achieving a 2.5 percentage-point net benefit at a threshold probability of ∼9%.
Conclusions
FOLFIRINOX appears the most effective option for carefully selected, fit patients eligible for 2L chemotherapy after GnP failure. Interpretable artificial intelligence-derived treatment policies may provide superior net clinical benefit compared to uniform approaches and guide individualized therapy, warranting integration with upcoming targeted strategies such as RAS inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, 35128, Italy.
- Department of Medical and Surgical Sciences, Policlinico Riuniti di Foggia, Unit of Medical Oncology and Biomolecular Therapy and University of Foggia, Foggia, 71122, Italy.
- Division of Oncology, Verona University and Hospital Trust (AOUI Verona), Verona, 37126, Italy.
- Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona, Verona, 37134, Italy.
- Medical Oncology, University Hospital and University of Cagliari, Cagliari, 09124, Italy.
- Department of Oncology, Academic Hospital of Udine ASUFC, Udine, 33100, Italy.
ORCID-Profile: Federico Nichetti, Monica Niger, Elena Ongaro, Mario Scartozzi
Förderung
- Ricerca Corrente funding from the Italian Ministry of Health
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Italian Ministry of University and Research
Zitieren
APA
Procaccio, L., Giordano, G., Nichetti, F., Milella, M., Pretta, A., Iacono, D., Niger, M., Casalino, S., Vivaldi, C., De Vita, F., Pusceddu, V., Landriscina, M., Di Paolo, G., Sperotto, S., Masucci, M., Tortora, G., Bianco, R., Vasile, E., Zaniboni, A., …, & Lonardi, S. (2026). Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. The Oncologist. https://doi.org/10.1093/oncolo/oyag085
Vancouver
Procaccio L, Giordano G, Nichetti F, Milella M, Pretta A, Iacono D, et al. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. The Oncologist. 2026. doi:10.1093/oncolo/oyag085
BibTeX
@article{Procaccio2026,
author = {Procaccio, Letizia and Giordano, Guido and Nichetti, Federico and Milella, Michele and Pretta, Andrea and Iacono, Donatella and Niger, Monica and Casalino, Simona and Vivaldi, Caterina and De Vita, Ferdinando and Pusceddu, Valeria and Landriscina, Matteo and Di Paolo, Giacomo and Sperotto, Sara and Masucci, Mariachiara and Tortora, Giampaolo and Bianco, Roberto and Vasile, Enrico and Zaniboni, Alberto and Miceli, Chiara Carmen and Ongaro, Elena and Giommoni, Elisa and Tinè, Gabriele and Barsotti, Giulia and Marchesi, Silvia and Di Marco, Mariacristina and Ortolani, Silvia and Aprile, Giuseppe and Scartozzi, Mario and Bergamo, Francesca and Melisi, Davide and Lonardi, Sara},
title = {Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag085}
}
EUVIMED